Your browser is no longer supported. Please, upgrade your browser.
Immunome, Inc.
Index- P/E- EPS (ttm)- Insider Own15.60% Shs Outstand10.81M Perf Week-24.61%
Market Cap322.57M Forward P/E- EPS next Y-1.80 Insider Trans5.20% Shs Float7.07M Perf Month36.26%
Income- PEG- EPS next Q-0.29 Inst Own19.20% Short Float1.02% Perf Quarter168.10%
Sales- P/S- EPS this Y-33.10% Inst Trans146.35% Short Ratio0.24 Perf Half Y-
Book/sh- P/B- EPS next Y79.10% ROA- Target Price36.00 Perf Year-
Cash/sh0.62 P/C48.14 EPS next 5Y- ROE- 52W Range9.27 - 63.78 Perf YTD208.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.21% Beta-
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low221.73% ATR5.91
Employees21 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)51.68 Volatility13.54% 20.09%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.33 Prev Close30.60
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume293.93K Price29.84
Recom1.50 SMA20-0.61% SMA5049.99% SMA20089.97% Volume99,384 Change-2.48%
Feb-18-21 07:06PM  
Feb-03-21 07:00AM  
Feb-01-21 07:00AM  
Jan-17-21 03:53AM  
Dec-10-20 08:00AM  
Nov-17-20 05:53PM  
Oct-13-20 04:05PM  
Oct-02-20 05:53PM  
Oct-01-20 08:23PM  
Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAPP MICHAELDirectorOct 06Buy12.0083,332999,984638,886Oct 08 06:16 PM